Goodwill and Other Intangible Assets (Tables)

6 Months Ended

Jul. 03, 2011

Schedule of changes in carrying amount of goodwill [Text Block]

The changes in the carrying amount of goodwill for the six months ended July 3, 2011, follow:

(millions of dollars)	Primary Care	Specialty Care and Oncology	Established Products and Emerging Markets	Animal Health and Consumer Healthcare		Nutrition		To be allocated(a)		Total
Balance, December 31, 2010	$	$	$	$	2,449	$	496	$	40,983	$	43,928
Additions(b)					—		—		791		791
Other(c)					16		10		362		388
Balance, July 3, 2011	$	$	$	$	2,465	$	506	$	42,136	$	45,107

(a) The amount to be allocated includes the former Biopharmaceutical goodwill (see below), as well as newly acquired goodwill from our acquisition of King, for which the allocation to reporting units is pending (see Note 3. Acquisition of King Pharmaceuticals, Inc. for additional information).

(b) Relates to our acquisition of King and is subject to change until we complete the recording of the assets acquired and liabilities assumed from King (see Note 3. Acquisition of King Pharmaceuticals, Inc.). The allocation of King goodwill among our reporting units has not yet been completed, but will be completed within one year of the acquisition date.

(c) Primarily reflects the impact of foreign exchange.

Schedule of identifiable intangible assets [Text Block]

The components of identifiable intangible assets follow:

	July 3, 2011							December 31, 2010
(millions of dollars)	Gross Carrying Amount		Accumulated Amortization			Identifiable Intangible Assets, less Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization			Identifiable Intangible Assets, less Accumulated Amortization
Finite-lived intangible assets:
Developed technology rights	$	71,354	$	(29,608	)	$	41,746	$	68,432	$	(26,223	)	$	42,209
Brands		1,710		(649	)		1,061		1,626		(607	)		1,019
License agreements		582		(254	)		328		637		(248	)		389
Trademarks and other		522		(322	)		200		533		(324	)		209
Total amortized finite-lived intangible assets		74,168		(30,833	)		43,335		71,228		(27,402	)		43,826
Indefinite-lived intangible assets:
Brands		10,285		—			10,285		10,219		—			10,219
In-process research and development		3,366		—			3,366		3,438		—			3,438
Trademarks		73		—			73		72		—			72
Total indefinite-lived intangible assets		13,724		—			13,724		13,729		—			13,729
Total identifiable intangible assets(a)	$	87,892	$	(30,833	)	$	57,059	$	84,957	$	(27,402	)	$	57,555

(a) The decrease is primarily related to amortization as well as impairment charges (see Note 6. Other (Income)/Deductions—Net) of intangible assets, partially offset by the assets acquired as part of the acquisition of King (see Note 3. Acquisition of King Pharmaceuticals, Inc.) and the impact of foreign exchange.